Dr. Duma is originally from Venezuela, born of a Colombian mother and Dominican father. She completed her internal medicine residency in Rutgers New Jersey Medical School, and her fellowship at the Mayo Clinic in Rochester, Minnesota, where she was the chief fellow from 2018 -2019.
Dr. Duma is the associate director of the Cancer Care Equity Program and a thoracic medical oncologist at the Dana-Farber Cancer Institute/Harvard Cancer Center.
Dr. Duma's clinical interests include targeted therapy for lung cancer and the care of women with lung cancer, including their unique aspects of cancer survivorship. She is the principal investigator of the Sexual Health Assessment in Women with Lung Cancer (SHAWL) Study, the largest study to date evaluating sexual dysfunction in women with lung cancer. Apart from her clinical interests in lung cancer, Dr. Duma is also a leading and productive researcher in cancer health disparities, including gender and racial discrimination in medical education and medicine. Dr. Duma in one of the co-founders of the Twitter community #LatinasInMedicine, now composed of more than 6,500 members globally. She has received many awards, including the 2018 Resident of the Year Award from the National Hispanic Medical Association, the Mayo Brothers Distinguished Fellowship award, and the 2020 Rising Star award from the LEAD national conference for women in hematology and oncology.
In 2019, Dr. Duma founded the Duma Lab, which focuses on lung cancer and social justice issues in medicine and medical education. The laboratory’s long-term goals are to create a welcoming environment for medical trainees from historically underrepresented groups in medicine while also improving the care of vulnerable populations. Dr. Duma’s work has been featured in various media outlets including The New York Times, STAT, Healio, Onclive, ASCO Post and Doximity.